Screening coverage needed to reduce mortality from prostate cancer: A living systematic review

PLoS ONE

Volumn 11, Issue 4, 2016, Pages

  Rahal, Ahmad K ^a   Badgett, Robert G ^a   Hoffman, Richard M ^b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; DATA ANALYSIS; GENETIC HETEROGENEITY; HUMAN; META ANALYSIS; PRACTICE GUIDELINE; PROSTATE CANCER; QUALITY CONTROL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SYSTEMATIC REVIEW; TRANSRECTAL ULTRASONOGRAPHY; MALE; MASS SCREENING; MORTALITY; PROCEDURES; PROSTATIC NEOPLASMS;

HUMANS; MALE; MASS SCREENING; PROSTATIC NEOPLASMS;

EID: 84963785271     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0153417     Document Type: Article

References (39)

1. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TL, et al. PLCO Project Team, mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009; 360(13):1310-9. doi: 10.1056/NEJMoa0810696 PMID: 19297565
2. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. ERSPC Investigators, screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009; 360 (13):1320-8. doi: 10.1056/NEJMoa0810084 PMID: 19297566
3. Ilic D, Neuberger MM, Djulbegovic M, Dahm P. Screening for prostate cancer. Cochrane Database Syst Rev. 2013; 1:CD004720. doi: 10.1002/14651858.CD004720.pub3 PMID: 23440794
4. Moyer VA. U.S. Preventive Services Task Force Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012; 157(2):120-34. doi: 10.7326/0003-4819-157-2-201207170-00459 PMID: 22801674
5. Canadian Task Force on Preventive Health Care, Bell N, Connor Gorber S, Shane A, Joffres M, Singh H, et al. Recommendations on screening for prostate cancer with the prostate-specific antigen test. CMAJ. 2014; 186(16):1225-34. doi: 10.1503/cmaj.140703 PMID: 25349003
6. Qaseem A, Barry MJ, Denberg TD, Owens DK, Shekelle P. Clinical Guidelines Committee of the American College of Physicians Screening for prostate cancer: A guidance statement from the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med. 2013; 158(10):761-9. doi: 10. 7326/0003-4819-158-10-201305210-00633 PMID: 23567643
7. Heidenreich A, Abrahamsson PA, Artibani W, Catto J, Montorsi F, Van Poppel H, et al. European Association of Urology. Early detection of prostate cancer: European Association of Urology recommendation. Eur Urol. 2013; 64(3):347-54. doi: 10.1016/j.eururo.2013.06.051 PMID: 23856038
8. Elliott JH, Turner T, Clavisi O, Thomas J, Higgins JP, Mavergames C, Gruen RL. Living systematic reviews: An emerging opportunity to narrow the evidence-practice gap. PLoS Med. 2014; 11(2): E1001603. doi: 10.1371/journal.pmed.1001603 PMID: 24558353
9. OpenMetaAnalysis Contributors. Methods. Version December 22, 2015. Available: Http://openmetaanalysis.github.io/methods.html. Accessed 18 Mar 2016
10. Badgett RG, Vindhyal M, Stirnaman JT, Gibson CM, Halaby R. A Living SystematicReview of Nebulized Hypertonic Saline for Acute Bronchiolitis in Infants. JAMAPediatr. 2015; 169(8):788-9.
11. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration. Ann Intern Med. 2009; 151(4):W65-94. PMID: 19622512
12. Grade Working Group. Methods. Available: Http://www.gradeworkinggroup.org/. Accessed 30 Apr 2015.
13. Open MetaAnalysis Contributors. Prostate cancer screening with prostate specific antigen. Version June 15, 2015. Available: Http://openmetaanalysis.github.io/Prostate-cancer-screening-with-prostatespecific-antigen/. Accessed 15 Jun 2015.
14. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. ERSPC Investigators. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med. 2012; 366(11):981-90. doi: 10.1056/NEJMoa1113135 PMID: 22417251
15. Pinsky PF, Blacka A, Kramer BS, Miller A, Prorok PC, Berg C. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Clin Trials. 2010; 7(4):303-11. doi: 10.1177/1740774510374091 PMID: 20571134
16. Roobol MJ, Kerkhof M, Schröder FH, Cuzick J, Sasieni P, Hakama M, et al. Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). Eur Urol. 2009; 56 (4):584-91. doi: 10.1016/j.eururo.2009.07.018 PMID: 19660851
17. Chou R, Croswell JM, Dana T, Bougatsos C, Blazina I, Fu R, Gleitsmann K, et al. Screening for prostate cancer: A review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2011; 155(11):762-71. doi: 10.7326/0003-4819-155-11-201112060-00375 PMID: 21984740
18. Cornell JE, Mulrow CD, Localio R, Stack CB, Meibohm AR, Guallar E, Goodman SN. Random-effects meta-analysis of inconsistent effects: A time for change. Ann Intern Med. 2014; 160(4):267-70. PMID: 24727843
19. R Core Team R: A Language and Environment for Statistical Computing. 2014 R Foundation for Statistical Computing. Available: Http://www.R-project.org. Accessed 16 Apr 2015.
20. Risk of bias tool. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. 2011 The Cochrane Collaboration. Available: Http://www.cochranehandbook. org. Accessed 25 Jun 2015.
21. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011; 64(4):383-94. doi: 10.1016/j.jclinepi.2010.04.026 PMID: 21195583
22. Riaz IB, Badgett RG. Epidural Corticosteroid Injections for Radiculopathy and Spinal Stenosis. Ann Intern Med. 2016 (in press).
23. Schwartz LM, Woloshin S, Welch HG. Using a drug facts box to communicate drug benefits and harms: Two randomized trials. Ann Intern Med. 2009;21; 150(8):516-27 PMID: 19221371
24. Kjellman A, Akre O, Norming U, Törnblom M, Gustafsson O. 15-year followup of a population based prostate cancer screening study. J Urol. 2009; 181(4):1615-21. doi: 10.1016/j.juro.2008.11.115 PMID: 19233435
25. Sandblom G, Varenhorst E, Rosell J, Löfman O, Carlsson P. Randomised prostate cancer screening trial: 20 year follow-up. BMJ. 2011; 342:d1539. doi: 10.1136/bmj.d1539 PMID: 21454449
26. Labrie F, Candas B, Cusan L, Gomez JL, Bélanger A, Brousseau G, et al. Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial. Prostate. 2004; 59(3):311-8. PMID: 15042607
27. Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P, et al. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol. 2010; 11 (8):725-32. doi: 10.1016/S1470-2045(10)70146-7 PMID: 20598634
28. General methods for Cochrane reviews. Identifying and measuring heterogeneity. Available: Http://handbook.cochrane.org/chapter-9/9-5-2-identifying-and-measuring-heterogeneity.htm. Accessed 16 Apr 2015.
29. Etzioni R, Cha R, Cowen ME. Serial prostate specific antigen screening for prostate cancer: A computer model evaluates competing strategies. J Urol. 1999; 162(3 Pt 1):741-8. PMID: 10458357
30. Ross KS, Carter HB, Pearson JD, Guess HA. Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection. JAMA. 2000; 284(11):1399-405. PMID: 10989402
31. Gulati R, Gore JL, Etzioni R. Comparative effectiveness of alternative prostate-specific antigen-based prostate cancer screening strategies: Model estimates of potential benefits and harms. Ann Intern Med. 2013; 158(3):145-53. doi: 10.7326/0003-4819-158-3-201302050-00003 PMID: 23381039
32. Wu GH, Auvinen A, Yen AM, Hakama M, Tammela TL, Stenman UH, et al. The impact of interscreening interval and age on prostate cancer screening with prostate-specific antigen. Eur Urol. 2012; 61 (5):1011-8. doi: 10.1016/j.eururo.2012.01.008 PMID: 22264679
33. Wilt TJ, Harris RP, Qaseem A. High Value Care Task Force of the American College of Physicians. Screening for cancer: Advice for high-value care from the American College of Physicians. Ann Intern Med. 2015; 19; 162(10):718-25. doi: 10.7326/M14-2326 PMID: 25984847
34. Nelson HD, Tyne K, Naik A, Bougatsos C, Chan BK, Humphrey L. U.S. Preventive Services Task Force Screening for breast cancer: An update for the U.S. Preventive Services Task Force. Ann Intern Med. 2009; 151(10):727-37, W237-42. doi: 10.7326/0003-4819-151-10-200911170-00009 PMID: 19920273
35. Elmunzer BJ, Singal AG, Sussman JB, Deshpande AR, Sussman DA, Conte ML, et al. Comparing the effectiveness of competing tests for reducing colorectal cancer mortality: A network meta-analysis. Gastrointest Endosc. 2015; 81(3):700-709.e3. doi: 10.1016/j.gie.2014.10.033 PMID: 25708757
36. Turner EL, Metcalfe C, Donovan JL, Nobel S, Sterne JA, Lane JA, et al. CAP trial group. Design and preliminary recruitment results of the Cluster randomised triAl of PSA testing for Prostate cancer (CAP). Br J Cancer. 2014; 110(12):2829-36. doi: 10.1038/bjc.2014.242 PMID: 24867688
37. Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2015; 65(1):5-29. doi: 10.3322/caac.21254 PMID: 25559415
38. Heijnsdijk EA, Wever EM, Auvinen A, Hugosson J, Ciatto S, Nelen V, et al. Quality-of-life effects of prostate-specific antigen screening. N Engl J Med. 2012; 367(7):595-605. doi: 10.1056/NEJMoa1201637 PMID: 22894572
39. Grewal S, Klassen TP. The tale of 2 trials: Disentangling contradictory evidence on hypertonic saline for acute bronchiolitis. JAMA Pediatr. 2014; 168(7):607-9. doi: 10.1001/jamapediatrics.2014.423 PMID: 24862208